IL301263A - BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY - Google Patents

Info

Publication number

IL301263A

IL301263A IL301263A IL30126323A IL301263A IL 301263 A IL301263 A IL 301263A IL 301263 A IL301263 A IL 301263A IL 30126323 A IL30126323 A IL 30126323A IL 301263 A IL301263 A IL 301263A

Authority

IL

Israel

Prior art keywords

amino acid

acid sequence

sequence seq

bispecific antibody

treatment

Prior art date

2020-11-18

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims description 376
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 348
• 102000003810 Interleukin-18 Human genes 0.000 claims description 319
• 108090000171 Interleukin-18 Proteins 0.000 claims description 319
• 241000282414 Homo sapiens Species 0.000 claims description 172
• 238000000034 method Methods 0.000 claims description 155
• 210000002966 serum Anatomy 0.000 claims description 127
• 108060003951 Immunoglobulin Proteins 0.000 claims description 113
• 102000018358 immunoglobulin Human genes 0.000 claims description 113
• 230000027455 binding Effects 0.000 claims description 108
• 230000002265 prevention Effects 0.000 claims description 105
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
• 230000035772 mutation Effects 0.000 claims description 90
• 201000010099 disease Diseases 0.000 claims description 81
• 229930105110 Cyclosporin A Natural products 0.000 claims description 60
• 108010036949 Cyclosporine Proteins 0.000 claims description 60
• 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 claims description 60
• 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 claims description 60
• 229960001265 ciclosporin Drugs 0.000 claims description 60
• 229930182912 cyclosporin Natural products 0.000 claims description 60
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 59
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 58
• 102100032752 C-reactive protein Human genes 0.000 claims description 58
• 102000008857 Ferritin Human genes 0.000 claims description 45
• 108050000784 Ferritin Proteins 0.000 claims description 45
• 238000008416 Ferritin Methods 0.000 claims description 45
• 239000003814 drug Substances 0.000 claims description 45
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 44
• 230000004048 modification Effects 0.000 claims description 40
• 238000012986 modification Methods 0.000 claims description 40
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims description 34
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 28
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 28
• 238000002560 therapeutic procedure Methods 0.000 claims description 28
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 27
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 27
• 230000007423 decrease Effects 0.000 claims description 25
• 238000005734 heterodimerization reaction Methods 0.000 claims description 24
• 208000010227 enterocolitis Diseases 0.000 claims description 21
• 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 19
• 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 18
• 230000002829 reductive effect Effects 0.000 claims description 16
• 101150034595 NLRC4 gene Proteins 0.000 claims description 14
• 230000000295 complement effect Effects 0.000 claims description 13
• 239000002773 nucleotide Substances 0.000 claims description 11
• 125000003729 nucleotide group Chemical group 0.000 claims description 11
• 238000011161 development Methods 0.000 claims description 9
• 229940124597 therapeutic agent Drugs 0.000 claims description 7
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 claims description 4
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 claims description 4
• 238000009097 single-agent therapy Methods 0.000 claims 1
• 206010052015 cytokine release syndrome Diseases 0.000 description 147
• 239000012634 fragment Substances 0.000 description 99
• 239000000427 antigen Substances 0.000 description 84
• 108091007433 antigens Proteins 0.000 description 84
• 102000036639 antigens Human genes 0.000 description 84
• 239000003862 glucocorticoid Substances 0.000 description 83
• 102000000589 Interleukin-1 Human genes 0.000 description 81
• 108010002352 Interleukin-1 Proteins 0.000 description 81
• 230000008685 targeting Effects 0.000 description 75
• 210000004027 cell Anatomy 0.000 description 73
• 230000004044 response Effects 0.000 description 71
• 238000012216 screening Methods 0.000 description 51
• 241001515942 marmosets Species 0.000 description 50
• 208000024891 symptom Diseases 0.000 description 48
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 42
• 238000012360 testing method Methods 0.000 description 39
• 108090000623 proteins and genes Proteins 0.000 description 38
• 230000009467 reduction Effects 0.000 description 37
• 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 34
• 210000004369 blood Anatomy 0.000 description 34
• 239000008280 blood Substances 0.000 description 34
• 108090000695 Cytokines Proteins 0.000 description 33
• 230000005764 inhibitory process Effects 0.000 description 33
• 102000004127 Cytokines Human genes 0.000 description 32
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 30
• 102000053602 DNA Human genes 0.000 description 30
• 108020004414 DNA Proteins 0.000 description 30
• 229940079593 drug Drugs 0.000 description 30
• 235000001014 amino acid Nutrition 0.000 description 29
• 238000003556 assay Methods 0.000 description 29
• 238000004519 manufacturing process Methods 0.000 description 28
• 238000006386 neutralization reaction Methods 0.000 description 27
• 230000009266 disease activity Effects 0.000 description 26
• 210000004602 germ cell Anatomy 0.000 description 25
• 230000036961 partial effect Effects 0.000 description 25
• 150000001413 amino acids Chemical class 0.000 description 24
• 230000014509 gene expression Effects 0.000 description 23
• 229940024606 amino acid Drugs 0.000 description 22
• 238000003745 diagnosis Methods 0.000 description 22
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 21
• 229960001838 canakinumab Drugs 0.000 description 21
• 230000002757 inflammatory effect Effects 0.000 description 21
• 206010037660 Pyrexia Diseases 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• 239000000203 mixture Substances 0.000 description 20
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 19
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 19
• 125000000539 amino acid group Chemical group 0.000 description 19
• 239000000090 biomarker Substances 0.000 description 19
• 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 18
• 102100036679 Interleukin-26 Human genes 0.000 description 17
• 230000009850 completed effect Effects 0.000 description 17
• 150000001875 compounds Chemical class 0.000 description 17
• 208000035475 disorder Diseases 0.000 description 17
• 239000000902 placebo Substances 0.000 description 16
• 229940068196 placebo Drugs 0.000 description 16
• 230000000638 stimulation Effects 0.000 description 16
• 208000011580 syndromic disease Diseases 0.000 description 16
• 108090001005 Interleukin-6 Proteins 0.000 description 15
• 102000004889 Interleukin-6 Human genes 0.000 description 15
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
• 238000011156 evaluation Methods 0.000 description 15
• 210000002950 fibroblast Anatomy 0.000 description 15
• 230000013595 glycosylation Effects 0.000 description 15
• 238000006206 glycosylation reaction Methods 0.000 description 15
• 239000002953 phosphate buffered saline Substances 0.000 description 15
• 239000012636 effector Substances 0.000 description 14
• 230000007774 longterm Effects 0.000 description 14
• 229920002477 rna polymer Polymers 0.000 description 14
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 13
• 238000013459 approach Methods 0.000 description 13
• 238000013461 design Methods 0.000 description 13
• 102000043959 human IL18 Human genes 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 238000012423 maintenance Methods 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 12
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 12
• 238000002965 ELISA Methods 0.000 description 12
• 108010034143 Inflammasomes Proteins 0.000 description 12
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 12
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 12
• 229960004238 anakinra Drugs 0.000 description 12
• 238000004458 analytical method Methods 0.000 description 12
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
• 230000007717 exclusion Effects 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 12
• 235000018102 proteins Nutrition 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 201000008827 tuberculosis Diseases 0.000 description 12
• 230000006870 function Effects 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 10
• 206010012735 Diarrhoea Diseases 0.000 description 10
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 10
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 10
• 230000000903 blocking effect Effects 0.000 description 10
• 210000004899 c-terminal region Anatomy 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 230000002500 effect on skin Effects 0.000 description 10
• 230000005847 immunogenicity Effects 0.000 description 10
• 230000003472 neutralizing effect Effects 0.000 description 10
• -1 polyethylene Polymers 0.000 description 10
• 229960004618 prednisone Drugs 0.000 description 10
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 10
• 150000003431 steroids Chemical class 0.000 description 10
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 9
• 208000010201 Exanthema Diseases 0.000 description 9
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 9
• 208000024780 Urticaria Diseases 0.000 description 9
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 9
• 201000005884 exanthem Diseases 0.000 description 9
• 238000002493 microarray Methods 0.000 description 9
• 206010037844 rash Diseases 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 230000000405 serological effect Effects 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 208000025721 COVID-19 Diseases 0.000 description 8
• 206010053567 Coagulopathies Diseases 0.000 description 8
• 206010033661 Pancytopenia Diseases 0.000 description 8
• 239000002202 Polyethylene glycol Substances 0.000 description 8
• 239000004743 Polypropylene Substances 0.000 description 8
• 230000033228 biological regulation Effects 0.000 description 8
• 208000024389 cytopenia Diseases 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 238000001802 infusion Methods 0.000 description 8
• 230000017306 interleukin-6 production Effects 0.000 description 8
• 208000019423 liver disease Diseases 0.000 description 8
• 230000005976 liver dysfunction Effects 0.000 description 8
• 238000002483 medication Methods 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 229920001155 polypropylene Polymers 0.000 description 8
• 230000035935 pregnancy Effects 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
• 238000006467 substitution reaction Methods 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 230000005856 abnormality Effects 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 208000015294 blood coagulation disease Diseases 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000036515 potency Effects 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 238000002255 vaccination Methods 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
• 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 6
• 206010020751 Hypersensitivity Diseases 0.000 description 6
• 208000001871 Tachycardia Diseases 0.000 description 6
• 208000026935 allergic disease Diseases 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 230000003466 anti-cipated effect Effects 0.000 description 6
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 229940109239 creatinine Drugs 0.000 description 6
• 230000009977 dual effect Effects 0.000 description 6
• 229950004645 emapalumab Drugs 0.000 description 6
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 238000011835 investigation Methods 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 230000000770 proinflammatory effect Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 230000006794 tachycardia Effects 0.000 description 6
• 108020004705 Codon Proteins 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 206010037868 Rash maculo-papular Diseases 0.000 description 5
• 230000000996 additive effect Effects 0.000 description 5
• 238000011970 concomitant therapy Methods 0.000 description 5
• 229940000406 drug candidate Drugs 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 230000035558 fertility Effects 0.000 description 5
• 230000002496 gastric effect Effects 0.000 description 5
• 230000030279 gene silencing Effects 0.000 description 5
• 208000002672 hepatitis B Diseases 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 208000012965 maculopapular rash Diseases 0.000 description 5
• 235000016709 nutrition Nutrition 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 230000003285 pharmacodynamic effect Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 201000000306 sarcoidosis Diseases 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000003319 supportive effect Effects 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 230000003442 weekly effect Effects 0.000 description 5
• 108010088751 Albumins Proteins 0.000 description 4
• 102000009027 Albumins Human genes 0.000 description 4
• 241000234587 Canna Species 0.000 description 4
• 235000005273 Canna coccinea Nutrition 0.000 description 4
• 241001432959 Chernes Species 0.000 description 4
• 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 208000005176 Hepatitis C Diseases 0.000 description 4
• 102100030703 Interleukin-22 Human genes 0.000 description 4
• 229930182816 L-glutamine Natural products 0.000 description 4
• 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 4
• 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 4
• 229930182555 Penicillin Natural products 0.000 description 4
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
• 238000011529 RT qPCR Methods 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 210000000601 blood cell Anatomy 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 229960001334 corticosteroids Drugs 0.000 description 4
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 230000001506 immunosuppresive effect Effects 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 239000002547 new drug Substances 0.000 description 4
• 230000035764 nutrition Effects 0.000 description 4
• 229940049954 penicillin Drugs 0.000 description 4
• 230000000306 recurrent effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 229940127558 rescue medication Drugs 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000002195 synergetic effect Effects 0.000 description 4
• 238000004448 titration Methods 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 238000005303 weighing Methods 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• 206010069754 Acquired gene mutation Diseases 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 238000000729 Fisher's exact test Methods 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• 102100035017 Interleukin-18-binding protein Human genes 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 208000036504 NLRC4-related familial cold autoinflammatory syndrome Diseases 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 3
• 238000002123 RNA extraction Methods 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000003409 anti-rejection Effects 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 238000010241 blood sampling Methods 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 238000000423 cell based assay Methods 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 229940124301 concurrent medication Drugs 0.000 description 3
• 239000003433 contraceptive agent Substances 0.000 description 3
• 230000002254 contraceptive effect Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 230000003054 hormonal effect Effects 0.000 description 3
• 230000009610 hypersensitivity Effects 0.000 description 3
• 230000002519 immonomodulatory effect Effects 0.000 description 3
• 229940124622 immune-modulator drug Drugs 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 102000004114 interleukin 20 Human genes 0.000 description 3
• 108090000681 interleukin 20 Proteins 0.000 description 3
• 102000044166 interleukin-18 binding protein Human genes 0.000 description 3
• 108010070145 interleukin-18 binding protein Proteins 0.000 description 3
• 108010074109 interleukin-22 Proteins 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000009533 lab test Methods 0.000 description 3
• 210000004901 leucine-rich repeat Anatomy 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• 230000035800 maturation Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 238000013546 non-drug therapy Methods 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 230000000474 nursing effect Effects 0.000 description 3
• 230000008816 organ damage Effects 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 238000000554 physical therapy Methods 0.000 description 3
• 102000040430 polynucleotide Human genes 0.000 description 3
• 108091033319 polynucleotide Proteins 0.000 description 3
• 239000002157 polynucleotide Substances 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 238000003908 quality control method Methods 0.000 description 3
• 230000036387 respiratory rate Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 239000012723 sample buffer Substances 0.000 description 3
• 238000005070 sampling Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 230000000392 somatic effect Effects 0.000 description 3
• 230000037439 somatic mutation Effects 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 229950008041 tadekinig alfa Drugs 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 239000003656 tris buffered saline Substances 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 101100472430 Arabidopsis thaliana RLP27 gene Proteins 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 208000011594 Autoinflammatory disease Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 208000009079 Bronchial Spasm Diseases 0.000 description 2
• 208000014181 Bronchial disease Diseases 0.000 description 2
• 206010006482 Bronchospasm Diseases 0.000 description 2
• 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
• 206010011674 Cutaneous sarcoidosis Diseases 0.000 description 2
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
• 206010072268 Drug-induced liver injury Diseases 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 108010040721 Flagellin Proteins 0.000 description 2
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
• 102000006471 Fucosyltransferases Human genes 0.000 description 2
• 108010019236 Fucosyltransferases Proteins 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 2
• 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 2
• 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 2
• 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
• 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
• 206010021118 Hypotonia Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 206010021639 Incontinence Diseases 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 206010024570 Lip swelling Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010068052 Mosaicism Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 208000007379 Muscle Hypotonia Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 208000037656 Respiratory Sounds Diseases 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 206010042241 Stridor Diseases 0.000 description 2
• 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102100030859 Tissue factor Human genes 0.000 description 2
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 206010047924 Wheezing Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 230000036783 anaphylactic response Effects 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 230000036760 body temperature Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 101150062912 cct3 gene Proteins 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 238000011067 equilibration Methods 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 201000003390 familial cold autoinflammatory syndrome 4 Diseases 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000012997 ficoll-paque Substances 0.000 description 2
• 238000011010 flushing procedure Methods 0.000 description 2
• 239000012909 foetal bovine serum Substances 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 101150023212 fut8 gene Proteins 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 208000014752 hemophagocytic syndrome Diseases 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 235000003642 hunger Nutrition 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 208000018875 hypoxemia Diseases 0.000 description 2
• 230000005931 immune cell recruitment Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 210000004561 lacrimal apparatus Anatomy 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 231100000706 no observed effect level Toxicity 0.000 description 2
• 238000006384 oligomerization reaction Methods 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 238000003068 pathway analysis Methods 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 238000009597 pregnancy test Methods 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
• 238000001303 quality assessment method Methods 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 208000026775 severe diarrhea Diseases 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 238000004088 simulation Methods 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 208000020352 skin basal cell carcinoma Diseases 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 201000003646 skin sarcoidosis Diseases 0.000 description 2
• 230000009469 supplementation Effects 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 206010042772 syncope Diseases 0.000 description 2
• 231100000378 teratogenic Toxicity 0.000 description 2
• 230000003390 teratogenic effect Effects 0.000 description 2
• 231100000041 toxicology testing Toxicity 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
• 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
• 241000191291 Abies alba Species 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• 208000026326 Adult-onset Still disease Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 102100030765 Apolipoprotein L4 Human genes 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010061728 Bone lesion Diseases 0.000 description 1
• 206010006102 Bradypnoea Diseases 0.000 description 1
• 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
• 102000002164 CARD domains Human genes 0.000 description 1
• 108050009503 CARD domains Proteins 0.000 description 1
• 102100038542 Calcium homeostasis modulator protein 6 Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000028399 Critical Illness Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
• 206010011891 Deafness neurosensory Diseases 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 208000035690 Familial cold urticaria Diseases 0.000 description 1
• 206010053172 Fatal outcomes Diseases 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 206010072240 Foetal placental thrombosis Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 208000007521 HIV Seropositivity Diseases 0.000 description 1
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 101000793444 Homo sapiens Apolipoprotein L4 Proteins 0.000 description 1
• 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
• 101000741361 Homo sapiens Calcium homeostasis modulator protein 6 Proteins 0.000 description 1
• 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
• 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101001121100 Homo sapiens Putative olfactory receptor 2I1 Proteins 0.000 description 1
• 101000879116 Homo sapiens Succinate receptor 1 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
• 101710199214 Interleukin-10 receptor subunit beta Proteins 0.000 description 1
• 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
• 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
• 102100039879 Interleukin-19 Human genes 0.000 description 1
• 108050009288 Interleukin-19 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 description 1
• 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 description 1
• 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 1
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 101000695835 Mus musculus Receptor-type tyrosine-protein phosphatase U Proteins 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 108091008099 NLRP3 inflammasome Proteins 0.000 description 1
• 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 102100026634 Putative olfactory receptor 2I1 Human genes 0.000 description 1
• 229940022005 RNA vaccine Drugs 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 108091006303 SLC2A9 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241001138501 Salmonella enterica Species 0.000 description 1
• 244000309727 Salmonella enterica serotype Enteritidis Species 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 241000607762 Shigella flexneri Species 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 102100037464 Succinate receptor 1 Human genes 0.000 description 1
• 239000006180 TBST buffer Substances 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 210000000068 Th17 cell Anatomy 0.000 description 1
• 208000037063 Thinness Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000007640 basal medium Substances 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229930189065 blasticidin Natural products 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 208000024336 bradypnea Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 238000011281 clinical therapy Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 208000035623 congenital anemia Diseases 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 238000009223 counseling Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 229960000860 dapsone Drugs 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000035487 diastolic blood pressure Effects 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000003027 ear inner Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 206010016165 failure to thrive Diseases 0.000 description 1
• 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000002550 fecal effect Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000037219 healthy weight Effects 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000011316 hemodynamic instability Diseases 0.000 description 1
• 206010019847 hepatosplenomegaly Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000052611 human IL6 Human genes 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008073 immune recognition Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 229940031551 inactivated vaccine Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 102000003898 interleukin-24 Human genes 0.000 description 1
• 108090000237 interleukin-24 Proteins 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 108700021021 mRNA Vaccine Proteins 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 238000010197 meta-analysis Methods 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 235000020925 non fasting Nutrition 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 229940023041 peptide vaccine Drugs 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
• 229960000215 ruxolitinib Drugs 0.000 description 1
• 231100000279 safety data Toxicity 0.000 description 1
• 238000009118 salvage therapy Methods 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229940083542 sodium Drugs 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000000954 titration curve Methods 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 235000021476 total parenteral nutrition Nutrition 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 206010048828 underweight Diseases 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 229940044953 vaginal ring Drugs 0.000 description 1
• 239000006213 vaginal ring Substances 0.000 description 1
• 229960004914 vedolizumab Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1